Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-CoV-2 Spike Protein for Neutralization Assays

Katharine H D Crawford; Rachel Eguia; Adam S Dingens; Andrea N Loes; Keara D Malone; Caitlin R Wolf; Helen Y Chu; M Alejandra Tortorici; David Veesler; Michael Murphy; Deleah Pettie; Neil P King; Alejandro B Balazs; Jesse D Bloom

doi:10.3390/v12050513

Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-CoV-2 Spike Protein for Neutralization Assays

Viruses. 2020 May 6;12(5):513. doi: 10.3390/v12050513.

Authors

Katharine H D Crawford^{1

2

3}, Rachel Eguia¹, Adam S Dingens¹, Andrea N Loes¹, Keara D Malone¹, Caitlin R Wolf⁴, Helen Y Chu⁴, M Alejandra Tortorici^{5

6}, David Veesler⁵, Michael Murphy⁷, Deleah Pettie⁷, Neil P King^{5

7}, Alejandro B Balazs⁸, Jesse D Bloom^{1

2

9}

Affiliations

¹ Division of Basic Sciences and Computational Biology Program, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
² Department of Genome Sciences, University of Washington, Seattle, WA 98195, USA.
³ Medical Scientist Training Program, University of Washington, Seattle, WA 98195, USA.
⁴ Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA 98195, USA.
⁵ Department of Biochemistry, University of Washington, Seattle, WA 98109, USA.
⁶ Institute Pasteur & CNRS UMR 3569, Unité de Virologie Structurale, 75015 Paris, France.
⁷ Institute for Protein Design, University of Washington, Seattle, WA 98195, USA.
⁸ The Ragon Institute of Massachusetts General Hospital, the Massachusetts Institute Technology, and Harvard University, Cambridge, MA 02139, USA.
⁹ Howard Hughes Medical Institute, Seattle, WA 98103, USA.

Abstract

SARS-CoV-2 enters cells using its Spike protein, which is also the main target of neutralizing antibodies. Therefore, assays to measure how antibodies and sera affect Spike-mediated viral infection are important for studying immunity. Because SARS-CoV-2 is a biosafety-level-3 virus, one way to simplify such assays is to pseudotype biosafety-level-2 viral particles with Spike. Such pseudotyping has now been described for single-cycle lentiviral, retroviral, and vesicular stomatitis virus (VSV) particles, but the reagents and protocols are not widely available. Here, we detailed how to effectively pseudotype lentiviral particles with SARS-CoV-2 Spike and infect 293T cells engineered to express the SARS-CoV-2 receptor, ACE2. We also made all the key experimental reagents available in the BEI Resources repository of ATCC and the NIH. Furthermore, we demonstrated how these pseudotyped lentiviral particles could be used to measure the neutralizing activity of human sera or plasma against SARS-CoV-2 in convenient luciferase-based assays, thereby providing a valuable complement to ELISA-based methods that measure antibody binding rather than neutralization.

Keywords: 293T-ACE2; ACE2; ALAYT; COVID-19; SARS-CoV-2; Spike; coronavirus; cytoplasmic tail; lentiviral pseudotype; luciferase; neutralization assay.

Publication types

Research Support, N.I.H., Intramural
Research Support, Non-U.S. Gov't

MeSH terms

Angiotensin-Converting Enzyme 2
Antibodies, Neutralizing / immunology
Antibodies, Viral / blood
Antibodies, Viral / immunology*
Containment of Biohazards
HEK293 Cells
Humans
Lentivirus
Neutralization Tests / methods*
Peptidyl-Dipeptidase A / metabolism
Plasma / immunology
Spike Glycoprotein, Coronavirus / analysis*

Substances

Antibodies, Neutralizing
Antibodies, Viral
Spike Glycoprotein, Coronavirus
spike protein, SARS-CoV-2
Peptidyl-Dipeptidase A
ACE2 protein, human
Angiotensin-Converting Enzyme 2

Abstract

Publication types

MeSH terms

Substances

Grants and funding